For its second fiscal quarter (ending June 30), Globus Medical Inc (NYSE: GMED) has reported a -60% decline in E.P.S. from $0.57 a year ago to $0.23 in the current quarter. This performance was $-0.45 short of the consensus estimate of $0.68. For the latest four quarters through June 30, E.P.S. were $0.30 compared to $2.04 a year ago — a decline of -85%.
Recent Price Action
Globus Medical Inc (NYSE: GMED) stock closed at $69.05 on 8/6/24 after an increase of 1.8%. This advance was accompanied by normal trading volume. The stock has declined -3.5% during the last week but has been exceptionally strong relative to the market over the last nine months.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be above the cost of capital, GMED is expected to continue to be a modest Value Builder.
Globus Medical has a current Value Trend Rating of A (Highest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing consistent signals. Globus Medical has a slightly positive Appreciation Score of 66 and a good Power Rating of 83, resulting in the Highest Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of A. This review will be completed in the next several days.
Be the first to comment